Fundamental dimension Equity attribute | BLFEPeer $0.00010.00% Cap $156.7KP/E -0.0x QuantScore47/100 | BIOAFPeer $0.00010.00% Cap $7.94KP/E -0.1x QuantScore23/100 | BNYNLeader $0.00020.00% Cap $286.0KP/E -0.0x QuantScore49/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
94/100 |
51/100 |
88/100 |
Valuation Multiples, PEG & DCF upside | 67/100 | 0/100 | 33/100 |
Health Piotroski, Altman Z, leverage & liquidity | 27/100 | 20/100 | 25/100 |
Growth Revenue / earnings growth & margins | 0/100 | 20/100 | 50/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -0.0x | -0.1x | -0.0x |
Forward P/E (next FY) | — | -0.0x | — |
EV / EBITDA (TTM) | -0.3x | -0.2x | 6.7x |
Price / Sales | 0.4x | 10.5x | 0.1x |
Price / Free Cash Flow | -0.2x | -0.1x | -0.2x |
PEG ratio | 0.00 | -0.01 | -0.00 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 4 / 9 | 2 / 9 | 3 / 9 |
Altman Z-Score | -935.52 (Distress) | -42.04 (Distress) | -11.41 (Distress) |
Total debt / equity | -0.27 | -0.99 | -235.96 |
Quick ratio | 0.1x | 0.7x | 1.0x |
Interest coverage | -25.2x | -7.5x | -0.7x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | — | -99.1% | -8.2% |
Net income growth YoY | -111716.6% | -523.8% | -34.3% |
Gross margin (TTM) | -239.3% | -45.6% | 100.0% |
Operating margin (FY) | -302.2% | -12784.5% | -31.9% |
FCF margin (FY) | -215.0% | -9636.9% | -36.7% |
5. Trailing price performancePrice change over period |
1M return | +0.0% | +0.0% | -0.0% |
3M return | +0.0% | +0.0% | -0.0% |
6M return | +9900.0% | +0.0% | -0.0% |
Year to date | +9900.0% | -50.0% | -0.0% |
1Y return | +9900.0% | -50.0% | -0.0% |
3Y return | 0.0% | -98.0% | +90.0% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $0.034 +33935.6% upside | $-0.0125 -12625.3% premium | $-22.56 -11874297.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |